Floatz logo

3-IODOBENZYLGUANIDINE (123I)

Cognitive Disorder

Mayo ClinicSmall moleculePhase 4 / ApprovedActive
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
73/ 100

Competitive context

131 Active assets in the Cognitive Disorder cohort.

Asset / SponsorPhaseRating
Nicotine
University of Southern California
Phase 2BBB
Oxybutynin
University of Alberta
Phase 4BBB
Metformin
Fudan University
Phase 4BB
Quetiapine
Emory University
Phase 4BB
Rivastigmine
VA Office of Research and Development
Phase 4BB

View all 50 →

Same molecule, other indications

3-IODOBENZYLGUANIDINE (123I) is also rated in:

Lewy body dementiaActive
BB
Indicative · Phase 4
65 / 100
View asset →
REM sleep behavior disorderActive
BB
Indicative · Phase 4
65 / 100
View asset →
dementiaActive
B
Indicative · Phase 4
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →